Literature DB >> 3861207

Perfusion of vasopressin within the rat brain suppresses prostaglandin E-hyperthermia.

W D Ruwe, A M Naylor, W L Veale.   

Abstract

These experiments were undertaken to determine whether arginine vasopressin (AVP) could suppress a prostaglandin hyperthermia and to localize sites of these actions in the rat. Prostaglandin E2 (PGE2) sensitive sites were localized in the ventral-septal area by microinjecting 200 ng/0.5 microliter of prostaglandin E2. During perfusion with an artificial CSF, PGE2 injected into the lateral cerebral ventricle evoked a hyperthermia of more than 1 degree C. Perfusion of 6.5 micrograms/ml of AVP markedly attenuated the PGE2-induced hyperthermia. These results suggest that AVP suppresses PGE2-induced hyperthermia in sites in which PGE2 evokes an increase in core temperature.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3861207     DOI: 10.1016/0006-8993(85)90150-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  Blockade of prostaglandin E1 hyperthermia by sodium salicylate given into the ventral septal area of the rat brain.

Authors:  S J Alexander; K E Cooper; W L Veale
Journal:  J Physiol       Date:  1987-03       Impact factor: 5.182

2.  Evidence supporting a role for endogenous vasopressin in fever suppression in the rat.

Authors:  K E Cooper; A M Naylor; W L Veale
Journal:  J Physiol       Date:  1987-06       Impact factor: 5.182

3.  Stimulation of vasopressin release in the ventral septum of the rat brain suppresses prostaglandin E1 fever.

Authors:  A M Naylor; Q J Pittman; W L Veale
Journal:  J Physiol       Date:  1988-05       Impact factor: 5.182

4.  Sodium salicylate: alternate mechanism of central antipyretic action in the rat.

Authors:  S J Alexander; K E Cooper; W L Veale
Journal:  Pflugers Arch       Date:  1989-03       Impact factor: 3.657

5.  Activation of Preoptic Arginine Vasopressin Neurons Induces Hyperthermia in Male Mice.

Authors:  Iustin V Tabarean
Journal:  Endocrinology       Date:  2021-02-01       Impact factor: 4.736

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.